Context Therapeutics (NASDAQ:CNTX) Receives Buy Rating from D. Boral Capital

D. Boral Capital restated their buy rating on shares of Context Therapeutics (NASDAQ:CNTX - Free Report) in a research note issued to investors on Wednesday morning,Benzinga reports. D. Boral Capital currently has a $9.00 price objective on the stock.

Other analysts have also recently issued reports about the company. Citizens Jmp raised Context Therapeutics to a "strong-buy" rating in a research note on Wednesday, January 8th. HC Wainwright restated a "buy" rating and set a $6.00 price objective on shares of Context Therapeutics in a report on Monday, September 23rd. Finally, JMP Securities initiated coverage on shares of Context Therapeutics in a research note on Wednesday, January 8th. They issued an "outperform" rating and a $4.00 price objective on the stock. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $6.33.

Context Therapeutics Stock Down 1.0 %

Shares of NASDAQ CNTX traded down $0.01 during trading on Wednesday, hitting $0.98. 684,737 shares of the company traded hands, compared to its average volume of 393,594. The firm has a market capitalization of $73.51 million, a P/E ratio of -1.08 and a beta of 2.10. The company has a 50-day moving average price of $1.40 and a 200-day moving average price of $1.90. Context Therapeutics has a 1 year low of $0.89 and a 1 year high of $2.75.

Context Therapeutics (NASDAQ:CNTX - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.11). Research analysts predict that Context Therapeutics will post -0.51 EPS for the current fiscal year.

Institutional Investors Weigh In On Context Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. State Street Corp raised its stake in Context Therapeutics by 21.5% in the 3rd quarter. State Street Corp now owns 111,907 shares of the company's stock valued at $219,000 after acquiring an additional 19,800 shares during the period. Renaissance Technologies LLC boosted its stake in shares of Context Therapeutics by 63.4% during the second quarter. Renaissance Technologies LLC now owns 65,200 shares of the company's stock valued at $131,000 after purchasing an additional 25,300 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new position in Context Therapeutics during the 3rd quarter worth about $89,000. Ally Bridge Group NY LLC increased its position in shares of Context Therapeutics by 159.8% during the second quarter. Ally Bridge Group NY LLC now owns 1,886,232 shares of the company's stock worth $3,782,000 after buying an additional 1,160,281 shares during the period. Finally, Affinity Asset Advisors LLC boosted its holdings in shares of Context Therapeutics by 392.4% during the 2nd quarter. Affinity Asset Advisors LLC now owns 1,619,140 shares of the company's stock worth $3,246,000 after buying an additional 1,290,323 shares in the last quarter. Institutional investors and hedge funds own 14.03% of the company's stock.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.